{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T04:09:23Z","timestamp":1767499763447},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:00:00Z","timestamp":1457481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This study was supported by grants from the subcommittees of the National List of Essential Medicine, Thailand."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40258-016-0228-3","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T06:08:43Z","timestamp":1457503723000},"page":"281-292","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand"],"prefix":"10.1007","volume":"14","author":[{"given":"Unchalee","family":"Permsuwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyameth","family":"Dilokthornsakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kednapa","family":"Thavorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surasak","family":"Saokaew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,9]]},"reference":[{"key":"228_CR1","unstructured":"Bureau of Policy and Strategy. Statistical Thailand 2014. Office of the Permanent Secretary, Ministry of Public Health; 2014."},{"key":"228_CR2","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.2337\/dc11-0099","volume":"34","author":"W Aekplakorn","year":"2011","unstructured":"Aekplakorn W, Chariyalertsak S, Kessomboon S, Sangthong P, Inthawong R, Putwatana P, et al. Prevalence and management of diabetes and metabolic risk factors in Thai adults. Diabetes Care. 2011;34:1980\u20135.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"228_CR3","first-page":"S1","volume":"89","author":"P Rawdaree","year":"2006","unstructured":"Rawdaree P, Ngarmukos C, Deerochanawong C, Suwanwalaikorn S, Chetthakul T, Krittiyawong S, et al. Thailand diabetes registry (TDR) project: clinical status and long term vascular complications in diabetic patients. J Med Assoc Thai. 2006;89(Suppl 1):S1\u20139.","journal-title":"J Med Assoc Thai"},{"key":"228_CR4","unstructured":"Pongcharoensuk P, Kongsaktrakool B, Tantivipanuwong S, Sema-ngern K, Chaiyakunapruk N. Costs of diabetes patients in Thai government hospitals. In: ISPOR 2nd Asia-Pacific Conference; Shanghai, China; 2006. p. 47."},{"key":"228_CR5","unstructured":"Diabetes Association of Thailand, Endocrine Society of Thailand, Department of Medicine Services Ministry of Public Health, National Health Security Office. Thai Clinical Practice Guideline for Diabetes 2014. Bangkok; 2014."},{"key":"228_CR6","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jval.2011.11.002","volume":"15","author":"S Ngorsuraches","year":"2012","unstructured":"Ngorsuraches S, Meng W, Kim BY, Kulsomboon V. Drug reimbursement decision making in Thailand, China, and South Korea. Value Health. 2012;15:S120\u20135.","journal-title":"Value Health."},{"key":"228_CR7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.zefq.2014.06.017","volume":"108","author":"Y Teerawattananon","year":"2014","unstructured":"Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwesen. 2014;108:397\u2013404.","journal-title":"Z Evid Fortbild Qual Gesundhwesen."},{"key":"228_CR8","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","volume":"29","author":"K Hermansen","year":"2006","unstructured":"Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269\u201374.","journal-title":"Diabetes Care"},{"key":"228_CR9","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1517\/14656566.2010.494831","volume":"11","author":"MG Jensen","year":"2010","unstructured":"Jensen MG, Hansen M, Brock B, Rungby J. Differences between long-acting insulins for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010;11:2027\u201335.","journal-title":"Expert Opin Pharmacother"},{"key":"228_CR10","first-page":"1","volume":"14","author":"N Waugh","year":"2010","unstructured":"Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1\u2013268.","journal-title":"Health Technol Assess"},{"key":"228_CR11","first-page":"1140","volume":"97","author":"P Rawdaree","year":"2014","unstructured":"Rawdaree P, Sarinnapakorn V, Pattanaungkul S, Khovidhunkit W, Tannirandorn P, Peerapatdit T. A prospective, longitudinal, multicenter, observational study to assess insulin treatment patterns in diabetic patients in Thailand: Results from the TITAN study. J Med Assoc Thai. 2014;97:1140\u201350.","journal-title":"J Med Assoc Thai"},{"issue":"Suppl 5","key":"228_CR12","first-page":"S10","volume":"97","author":"P Tanvejsilp","year":"2014","unstructured":"Tanvejsilp P, Ngorsuraches S. Defining the scope of health technology assessment and types of health economic evaluation. J Med Assoc Thai. 2014;97(Suppl 5):S10\u20136.","journal-title":"J Med Assoc Thai"},{"issue":"Suppl 1","key":"228_CR13","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1185\/030079904X1980","volume":"20","author":"AJ Palmer","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (type 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5\u201326.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"228_CR14","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1185\/030079904X2006","volume":"20","author":"AJ Palmer","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(Suppl 1):S27\u201340.","journal-title":"Curr Med Res Opin"},{"key":"228_CR15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977\u201386.","journal-title":"N Engl J Med"},{"key":"228_CR16","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"issue":"3","key":"228_CR17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, D\u2019Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22(3):312\u20138.","journal-title":"Stroke"},{"issue":"2","key":"228_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/archopht.1989.01070010243030","volume":"107","author":"R Klein","year":"1989","unstructured":"Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1989;107(2):237\u201343.","journal-title":"Arch Ophthalmol"},{"key":"228_CR19","unstructured":"World Health Organization. Life tables by country: Thailand. 2014 [October 15, 2014]; Available from: http:\/\/apps.who.int\/gho\/data\/?theme=main&vid=61640 ."},{"issue":"Supp 1","key":"228_CR20","first-page":"S66","volume":"89","author":"N Kosachunhanun","year":"2006","unstructured":"Kosachunhanun N, Benjasuratwong Y, Mongkolsomlit S, Rawdaree P, Plengvidhya N, Leelawatana R, et al. Thailand Diabetes Registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. J Med Assoc Thai. 2006;89(Supp 1):S66\u201371.","journal-title":"J Med Assoc Thai"},{"issue":"Suppl2","key":"228_CR21","first-page":"S1","volume":"94","author":"U Krairittichai","year":"2011","unstructured":"Krairittichai U, Potisat S, Jongsareejit A, Sattaputh C. Prevalence and risk factors of diabetic nephropathy among Thai patients with type2 diabetes mellitus. J Med Assoc Thai. 2011;94(Suppl2):S1\u20135.","journal-title":"J Med Assoc Thai"},{"key":"228_CR22","unstructured":"Rangsin R, Tatsanavivat P, MedResNet. An assessment on quality of care among patients diagnosed with type 2 diabetes and hypertension visiting hospitals of Ministry of Public Health and Bangkok Metropolitan Administration in Thailand, 2012. Thailand: National Health Security Office (NHSO); 2012."},{"key":"228_CR23","first-page":"65","volume":"90","author":"W Nitiyanant","year":"2007","unstructured":"Nitiyanant W, Chetthakul T, Sang-A-kad P, Therakiatkumjorn C, Kunsuikmengrai K, Yeo JP. A survey study on diabetes management and complication status in primary care setting in Thailand. J Med Assoc Thai. 2007;90:65\u201371.","journal-title":"J Med Assoc Thai"},{"key":"228_CR24","first-page":"716","volume":"91","author":"S Supapluksakul","year":"2008","unstructured":"Supapluksakul S, Ruamviboonsuk P, Chaowakul W. The prevalence of diabetic retinopathy in Trang province determined by retinal photography and comprehensive eye examination. J Med Assoc Thai. 2008;91:716\u201322.","journal-title":"J Med Assoc Thai"},{"key":"228_CR25","unstructured":"The Endocrine Society of Thailand. Diabetes Registry Project 2003. Health Systems Research Institute; 2004."},{"key":"228_CR26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jdiacomp.2013.12.002","volume":"28","author":"S Chuengsamarn","year":"2014","unstructured":"Chuengsamarn S, Rattanamongkolgul S, Jirawatnotai S. Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes. J Diabetes Complicat. 2014;28:124\u20139.","journal-title":"J Diabetes Complicat"},{"key":"228_CR27","first-page":"383","volume":"3","author":"T Thaneerat","year":"2009","unstructured":"Thaneerat T, Tangwongchai S. Prevalence of depression, hemoglobin A1c level, and associated factors in outpatients with type 2 diabetes. Asian Biomed (Res Rev News). 2009;3:383\u201390.","journal-title":"Asian Biomed (Res Rev News)."},{"key":"228_CR28","volume-title":"Cost-effectiveness analysis of diabetic retinopathy screening in type 2 diabetes mellitus [Master Thesis]","author":"S Pornpinatepong","year":"2005","unstructured":"Pornpinatepong S. Cost-effectiveness analysis of diabetic retinopathy screening in type 2 diabetes mellitus [Master Thesis]. Bangkok: Mahidol University; 2005."},{"key":"228_CR29","unstructured":"Riewpaiboon A. Standard cost lists for health technology assessment. Health Intervention and Technology Assessment Program (HITAP); 2011."},{"key":"228_CR30","unstructured":"National Statistical Office. Health. 2007 [15 October 2014]. Available from: http:\/\/web.nso.go.th\/en\/survey\/bts\/datafiles\/560619_09_Health.pdf ."},{"key":"228_CR31","unstructured":"Thamarangsi T. The situation of alcohol beaverage consumption and impact in Thailand 2013. Center for Alcohol Studies, International Health Policy Program, Ministry of Public Health; 2013."},{"key":"228_CR32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1524-4733.2006.00145.x","volume":"10","author":"Y Teerawattananon","year":"2007","unstructured":"Teerawattananon Y, Mugford M, Tangcharoensathien V. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health. 2007;10:61\u201372.","journal-title":"Value Health."},{"key":"228_CR33","unstructured":"Maharaj Nakorn Chiang Mai Hospital. Pharmacy and Healthcare Service Fees. Chiang Mai; 2014."},{"key":"228_CR34","unstructured":"King Chulalongkorn Memorial Hospital. Pharmacy and Healthcare Service Fees. Bangkok; 2014."},{"key":"228_CR35","unstructured":"National Health Security Office. Schedule of Health Benefits and Fees. Bangkok; 2014."},{"key":"228_CR36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/027298902400448902","volume":"22","author":"P Clarke","year":"2002","unstructured":"Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Mak. 2002;22:340\u20139.","journal-title":"Med Decis Mak"},{"key":"228_CR37","volume-title":"Economic evaluation of HMG-CoA reductase inhibitors (statin) for primary prevention of cardiovascular diseases among Thai population (in Thai language)","author":"Y Tamteerano","year":"2008","unstructured":"Tamteerano Y, Khonputsa P, Chaikledkaew U, Teerawattananon Y, Lim S. Economic evaluation of HMG-CoA reductase inhibitors (statin) for primary prevention of cardiovascular diseases among Thai population (in Thai language). Bangkok: Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health; 2008."},{"key":"228_CR38","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","volume":"38","author":"TO Tengs","year":"2000","unstructured":"Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583\u2013637.","journal-title":"Med Care"},{"key":"228_CR39","unstructured":"Australian Institute of Health and Welfare. The Burden of Disease and Injury in Australia; 2003."},{"key":"228_CR40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0168-8227(96)01198-9","volume":"32","author":"AL Carrington","year":"1996","unstructured":"Carrington AL, Mawdsley SK, Morley M, Kincey J, Boulton AJ. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract. 1996;32:19\u201325.","journal-title":"Diabetes Res Clin Pract"},{"key":"228_CR41","unstructured":"National Institute for Clinical Excellence. Guidance on the use of long-acting insulin analogues for the treatment of diabetes\u2014insulin glargine\u00a02002 Contract No.: 53."},{"key":"228_CR42","doi-asserted-by":"crossref","unstructured":"Emerging risk factors collaboration, Seshasai SR, Kaptonge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829\u201341.","DOI":"10.1056\/NEJMoa1008862"},{"key":"228_CR43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archinte.167.11.1145","volume":"167","author":"OH Franco","year":"2007","unstructured":"Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Association of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167:1145\u201351.","journal-title":"Arch Intern Med"},{"key":"228_CR44","unstructured":"Canadian Agency for Drugs and Technologies in Health. Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008."},{"key":"228_CR45","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.diabres.2010.05.008","volume":"89","author":"SP Chan","year":"2010","unstructured":"Chan SP, Ji LN, Nitiyanant W, Baik SH, Sheu WH. Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific: Real-life effectiveness and care patterns of diabetes management: The RECAP-DM study. Diabetes Res Clin Pract. 2010;89:e30\u20132.","journal-title":"Diabetes Res Clin Pract"},{"key":"228_CR46","unstructured":"Meeting summary of the National Drug Selection Working Group in Endocrine Number 4\/2014 (Thai language). Food and Drug Administration, 3 October 2014."},{"key":"228_CR47","unstructured":"Drug and Medical Supply Information Center. 2014 [Nov 2, 2014]; Available from: http:\/\/dmsic.moph.go.th ."},{"issue":"Suppl 5","key":"228_CR48","first-page":"S17","volume":"97","author":"A Riewpaiboon","year":"2014","unstructured":"Riewpaiboon A. Measurement of costs for health economic evaluation. J Med Assoc Thai. 2014;97(Suppl 5):S17\u201326.","journal-title":"J Med Assoc Thai"},{"key":"228_CR49","unstructured":"Bureau of Trade and Economics Indices, Ministry of Commerce. CPI 2014 [October 12, 2014]; Available from: www.price.moc.go.th\/price\/cpi\/index_new_e.asp ."},{"key":"228_CR50","unstructured":"Bank of Thailand. Foreign exchange rates 2015 [June 25, 2015]; Available from: https:\/\/www.bot.or.th\/english\/statistics\/financialmarkets\/exchangerate\/_layouts\/application\/exchangerate\/ExchangeRate.aspx ."},{"issue":"Suppl 5","key":"228_CR51","first-page":"S50","volume":"97","author":"U Permsuwan","year":"2014","unstructured":"Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai. 2014;97(Suppl 5):S50\u20138.","journal-title":"J Med Assoc Thai"},{"key":"228_CR52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CEOR.S38062","volume":"5","author":"M Thavorncharoensap","year":"2013","unstructured":"Thavorncharoensap M, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res. 2013;5:29\u201336.","journal-title":"Clinicoecon Outcomes Res."},{"key":"228_CR53","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/0272989X0002000308","volume":"20","author":"EF Halpern","year":"2000","unstructured":"Halpern EF, Weinstein MC, Hunink MG, Gazelle GS. Representing both first- and second-order uncertainties by Monte Carlo Simulation for groups of patients. Med Decis Mak. 2000;20:314\u201322.","journal-title":"Med Decis Mak"},{"key":"228_CR54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5414\/CPP49217","volume":"49","author":"M Brandle","year":"2011","unstructured":"Brandle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther. 2011;49:217\u201330.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"228_CR55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00019053-200725030-00007","volume":"25","author":"DT Grima","year":"2007","unstructured":"Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and type 2 diabetes in Canada. Pharmacoeconomics. 2007;25:253\u201366.","journal-title":"Pharmacoeconomics."},{"issue":"Suppl 1","key":"228_CR56","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1185\/030079907X167570","volume":"23","author":"P McEwan","year":"2007","unstructured":"McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin. 2007;23(Suppl 1):S21\u201331.","journal-title":"Curr Med Res Opin"},{"key":"228_CR57","unstructured":"National Health Security Office. An assessment on quality of care among patients diagnosed with type 2 diabetes and hypertension visiting hospital of Ministry of Public Health and Bangkok Metropolitan Administry in Thailand. 2014; Available from: http:\/\/dmht.thaimedresnet.org\/files_2558\/57DMHT_2014_ALL_Ontour.pdf ."},{"key":"228_CR58","unstructured":"Health Technology Assessment Working Team. Health Technology Assessment in Thailand, 2nd ed. Nonthaburi; 2014."},{"key":"228_CR59","unstructured":"Pemsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S. Cost-effectiveness analysis of Insulin Glargine in the treatment of type 2 diabetes. National List of Essential Medicine; 2014."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-016-0228-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-016-0228-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-016-0228-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:42Z","timestamp":1559503722000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-016-0228-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,9]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["228"],"URL":"https:\/\/doi.org\/10.1007\/s40258-016-0228-3","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,9]]}}}